Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
CC transcript
Appointed director
SANGAMO THERAPEUTICS, INC (SGMO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G/A WASATCH ADVISORS LP reports a 10.2% stake in Sangamo Therapeutics, Inc.
09/28/2023 4 BIOGEN INC. (10% Owner) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Sold 6,000,000 shares @ $0.5, valued at $3M
08/15/2023 4 Willoughby Scott B. (SVP, Gen. Counsel & Secretary) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Paid exercise price by delivering 864 shares @ $1.08, valued at $933.1
08/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2023 FINANCIAL RESULTS"
06/05/2023 4 Smith Karen L. (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Granted 13,900 shares @ $0
Granted 27,750 options to buy @ $1.11, valued at $30.8k
06/05/2023 4 PARKER H STEWART (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Granted 13,900 shares @ $0
Granted 27,750 options to buy @ $1.11, valued at $30.8k
06/05/2023 4 Meyers James R (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Granted 13,900 shares @ $0
Granted 27,750 options to buy @ $1.11, valued at $30.8k
06/05/2023 4 Markels John (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Granted 13,900 shares @ $0
Granted 27,750 options to buy @ $1.11, valued at $30.8k
06/05/2023 4 Horn Margaret A (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Granted 13,900 shares @ $0
Granted 27,750 options to buy @ $1.11, valued at $30.8k
06/05/2023 4 Hillan Kenneth J. (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Granted 13,900 shares @ $0
Granted 27,750 options to buy @ $1.11, valued at $30.8k
06/05/2023 4 Carey Robert (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Granted 13,900 shares @ $0
Granted 27,750 options to buy @ $1.11, valued at $30.8k
06/05/2023 4 Beers Courtney (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Granted 13,900 shares @ $0
Granted 27,750 options to buy @ $1.11, valued at $30.8k
06/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FIFTH CERTIFICATE OF AMENDMENT OF THE SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"SIXTH CERTIFICATE OF AMENDMENT OF THE SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"RESTATED CERTIFICATE OF INCORPORATION",
"2. SHARES SUBJECT TO THE PLAN."
05/30/2023 4 Willoughby Scott B. (SVP, Gen. Counsel & Secretary) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Paid exercise price by delivering 1,328 shares @ $1.33, valued at $1.8k
05/30/2023 4 Ramelmeier Rolf Andrew (EVP, Technical Operations) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Paid exercise price by delivering 1,750 shares @ $1.33, valued at $2.3k
05/30/2023 4 McClung David Mark (EVP, COO) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Paid exercise price by delivering 1,925 shares @ $1.33, valued at $2.6k
05/30/2023 4 Dubois-Stringfellow Nathalie (SVP-Chief Development Officer) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Paid exercise price by delivering 1,462 shares @ $1.33, valued at $1.9k
05/30/2023 4 Fontenot Jason D. (SVP, Chief Scientific Officer) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Paid exercise price by delivering 1,029 shares @ $1.33, valued at $1.4k
05/30/2023 4 Duraibabu Prathyusha (SVP, CFO) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Paid exercise price by delivering 1,328 shares @ $1.33, valued at $1.8k
05/30/2023 4 Macrae Sandy (President, CEO and Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
Txns: Paid exercise price by delivering 10,411 shares @ $1.33, valued at $13.8k
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/26/2023 8-K Quarterly results
04/26/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/17/2023 ARS Form ARS - Annual Report to Security Holders:
04/17/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/05/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/17/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
03/14/2023 8-K Other Events  Interactive Data
03/10/2023 8-K Other Events  Interactive Data
03/07/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy